RTTNews) - Biogen Idec (BIIB: News ) said Thursday it would present data on the company's leading multiple sclerosis or MS products-Tysabri, Avonex, as well as its pipeline of products, at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.
The company said the data would provide physicians with new information about the benefits of Tysabri and Avonex, and also update the MS community on the company's progress in its investigational compounds - daclizumab, Rituxan and BG-12, the company's novel oral compound that is in Phase III trials.
In addition, Biogen announced that the U.S. FDA had granted Fast Track Designation to BG-12. BG-12 is an oral formulation of dimethyl fumarate in development for MS. The benefits of Fast Track include scheduled meetings to seek FDA input into development plans, the option of submitting a New Drug Application in sections rather than all components simultaneously, and the option of requesting evaluation of studies using surrogate endpoints.
CLICK HERE FOR FULL ARTICLE & RELATED INFO